Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing the Ketogenic Effect of Coconut Oil and Different MCTs (Coco-MCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02679222
Recruitment Status : Completed
First Posted : February 10, 2016
Last Update Posted : March 29, 2017
Sponsor:
Information provided by (Responsible Party):
Université de Sherbrooke

Brief Summary:
The aim of this study is to compare the ketogenic effect of coconut oil and three MCT oils (60-40 , tricaprylin and triheptanoate) on the production of ketones in healthy adults. Each oil are evaluated individually or in combination over a 8h-period during which repeated blood sampling is performed.

Condition or disease Intervention/treatment Phase
Healthy Adults Dietary Supplement: Supplementation Not Applicable

Detailed Description:
The study is composed of eight successive visits. Each visit consists of the consumption of one individual oil or a mixture of oils (20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate) and a 8h follow-up during which repeated blood samples are taken for laboratory analysis (plasma beta-hydroxybutyrate, acetoacetate, glucose, free fatty acids, triglycerides, total cholesterol, lactate and insulin).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides
Actual Study Start Date : June 2015
Actual Primary Completion Date : December 2016
Actual Study Completion Date : March 1, 2017

Arm Intervention/treatment
Experimental: Supplementation
Oral intake of one of the supplements: 20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate
Dietary Supplement: Supplementation
coconut oil and MCT oils (60-40, tricaprylin and triheptanoate)




Primary Outcome Measures :
  1. Plasma ketone concentrations [ Time Frame: 8 hours ]
    Acetoacetate (uM) and beta-hydroxybutyrate (uM)


Secondary Outcome Measures :
  1. Plasma glucose concentrations [ Time Frame: 8 hours ]
    Glucose (mM)

  2. Plasma cholesterol concentrations [ Time Frame: 8 hours ]
    Total cholesterol (mM)

  3. Plasma free fatty acid concentrations [ Time Frame: 8 hours ]
    Triglycerides (mM)

  4. Plasma triglyceride concentrations [ Time Frame: 8 hours ]
    Triglycerides (mM)

  5. Plasma insulin concentrations [ Time Frame: 8 hours ]
    Insulin (IU/L)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult over 18 y old.

Exclusion Criteria:

  • Fasting plasma glucose ≥7.0 mM (diabetics or pre-diabetics);
  • Smoking
  • Clinically-significant gastro-intestinal disease/conditions.
  • Clinically-significant liver disease/dysfunction.
  • Clinically-significant cardiac disease/conditions.
  • Clinically-significant abnormal coagulation.
  • Taking a medication that could affect lipid and glucose metabolism
  • Hypertension
  • Pregnancy or breastfeeding
  • Exercising more than 3 times a week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02679222


Locations
Layout table for location information
Canada, Quebec
Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)
Sherbrooke, Quebec, Canada, J1H4C4
Sponsors and Collaborators
Université de Sherbrooke
Investigators
Layout table for investigator information
Principal Investigator: Stephen Cunnane, PhD CSSS-IUGS - CIUSSS de L'Estrie - CHUS - Université de Sherbrooke

Layout table for additonal information
Responsible Party: Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT02679222    
Other Study ID Numbers: 2016-541
First Posted: February 10, 2016    Key Record Dates
Last Update Posted: March 29, 2017
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided